Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins
about
Human parvovirus B19.Passive immunity in prevention and treatment of infectious diseasesParvovirus B19 infection in human pregnancyStructural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based ImmunogensFunctional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individualsTargeted killing of virally infected cells by radiolabeled antibodies to viral proteinsLongitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodiesPre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradicationAnti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypesThe VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity.Erythroid progenitor cells expanded from peripheral blood without mobilization or preselection: molecular characteristics and functional competence.Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes.Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.Effect of soluble CD4 on exposure of epitopes on primary, intact, native human immunodeficiency virus type 1 virions of different genetic clades.New LightCycler PCR for rapid and sensitive quantification of parvovirus B19 DNA guides therapeutic decision-making in relapsing infectionsStructural conservation predominates over sequence variability in the crown of HIV type 1's V3 loop.Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.Different pattern of immunoglobulin gene usage by HIV-1 compared to non-HIV-1 antibodies derived from the same infected subjectGlobal panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodiesIdentification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.High mutant frequency in populations of a DNA virus allows evasion from antibody therapy in an immunodeficient hostStructure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity.Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.The globoside receptor triggers structural changes in the B19 virus capsid that facilitate virus internalizationParvovirus B19 - Revised.Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2.Radiolabeled antibodies for therapy of infectious diseases.Human immunodeficiency virus type 1 evades T-helper responses by exploiting antibodies that suppress antigen processingLong term follow up of serostatus after maternofetal parvovirus B19 infectionCytokine gene polymorphisms associated with symptomatic parvovirus B19 infection.A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.Receptor-activating autoantibodies and disease: preeclampsia and beyond.Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFLProduction and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.A fully human antibody to gp41 selectively eliminates HIV-infected cells that transmigrated across a model human blood brain barrierIn vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120.The Receptor-Binding Domain in the VP1u Region of Parvovirus B19.The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.
P2860
Q24532891-B1D1EC20-06EA-40F6-A6BB-062AD85C40E2Q24550699-50370921-C95B-4719-94E1-B5A06F852565Q24594590-F7F89A4A-30A4-4906-BE18-80ED76BED885Q27658173-47F95455-5BF7-4ADC-B405-08DDF5828929Q27677941-CD63AD6E-AD73-4655-8EFA-CA3823064426Q28469068-D573E4D8-1DC8-45D8-B1A2-5F4B506772E4Q28477253-C7503F60-E336-4DB7-8E5E-C4DD37858AEBQ28731318-641E27AD-F232-40EF-967D-3ACD3AAFD5B0Q28752503-1D8A6DD0-6A10-4457-8F57-1C93BECDB051Q33340668-D374B4F2-2A1B-45C7-92E7-C88523132191Q33538033-EE36F77B-6A27-465C-A385-3DD639D16CEFQ33787329-5878767E-F4C5-4919-9FF6-D682797DE9DEQ33807129-9BBD34B8-1C9B-4506-82F8-9D94921F2CF3Q33809112-C10CC8FC-2AB3-48F9-91D5-F656D8651578Q33853226-C6305892-67EF-486C-8917-9BD1B8387F51Q33974299-0A0C8083-5C10-4974-8FB8-88F402C59F1BQ34100194-F6E56FD1-47A1-41E5-9589-0D864A28CE73Q34145199-F51741A6-650E-4660-A347-36533BA837EAQ34326222-5ACD752D-BE92-4113-804E-09A9E5ADF8C7Q34392963-846C9CBA-77DF-4626-9DC7-CE4F7AE6C6EFQ34406977-329EF6FE-BF8D-4308-B852-5B42D963A137Q34472287-1E3FD0A7-BEC3-4251-B409-B2205265F1E4Q34499013-7B737910-5632-4CA4-A0FF-63916F71D6A6Q34543052-BB94BE38-DD1C-48E2-BF3F-E5AE9DD63BE3Q34623255-B1ADCDCD-D367-4D03-8449-F24B6A62C77EQ34625443-F4021E02-BF06-4914-A942-3082370A2BAAQ34907398-4B6611D1-BCA1-40B6-A459-1AF9D0B83765Q34955947-80ADB021-09DC-4BF5-9552-2E2633287FA1Q35122914-5CE2D3F8-AA73-45F0-8A61-67D39D017685Q35275671-98907B83-9AED-4E4B-A58D-A5ED5D94F13BQ35587076-F4B5244A-E10A-4182-B982-F690EF22A292Q35706462-9565E002-0D0B-40BC-AF71-8B07435FB635Q35707881-0027431E-D0B7-4E29-A857-7CD236513E08Q35817106-7CC31F1E-9E39-423D-8E25-0F983B2FB215Q35913910-8063AB4C-6B2F-481D-A37B-D6DA77685E07Q36384117-B3752E70-5BDC-47E5-A461-73F2C5DC4F6DQ36522639-44517677-7B04-47F4-8F81-1CC4B4F576FEQ36529013-E68F4F1F-C8F0-4DDB-80D2-37F22B3A4DB1Q36735626-23020297-40C8-48CE-9319-47F724C84B38Q36954472-1D2185F5-C568-490F-81E6-D8CDCF678FD5
P2860
Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins
@ast
Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins
@en
type
label
Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins
@ast
Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins
@en
prefLabel
Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins
@ast
Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins
@en
P2093
P2860
P1433
P1476
Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins
@en
P2093
C Williams
S Zolla-Pazner
P2860
P304
P577
1999-03-01T00:00:00Z